# KPV Legal Status, FDA 503A Category, and Compounding Access | KPV peptide | KPV Store
> KPV legal status: the KPV peptide is a research peptide, not FDA-approved, and is individually named on the July 23-24, 2026 PCAC agenda as a substance being considered for the 503A bulks list. Current FDA facts, cited; no decision asserted.
Access to compounded KPV is under active FDA review and may expand in 2026. Here is exactly what that means — and what it does not — stated present-tense and cited to the FDA.
## The short version
Here is the KPV legal status in plain words. KPV is a research peptide, not an FDA-approved drug for anything. The forward-leaning, genuinely real news: the FDA's Pharmacy Compounding Advisory Committee (PCAC) has a meeting scheduled for July 23-24, 2026, and KPV is named on the published agenda as a substance "being considered for inclusion on the 503A Bulks List" [18]. That is a scheduled discussion, not a decision, not a reclassification, and not a change in today's status. In short: access is under active review and may expand in 2026, but as of now KPV is a research-only peptide, and nothing here is an offer to sell or supply it.
## The Forward-Leaning Fact: KPV Is on the July 2026 PCAC Agenda
The momentum is concrete and worth stating first. KPV is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [18]. FDA's calendar lists KPV in both its free-base and acetate forms, and the same agenda also lists BPC-157, TB-500, and MOTs-C [18]. In that precise sense, access to compounded KPV is under active FDA review and may expand in 2026.
That momentum has a firm boundary, and the boundary is the honest part. A PCAC agenda item is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in KPV's current status [18]. The committee is advisory; inclusion on a final 503A bulks list is decided by FDA rulemaking, informed by — but not bound by — PCAC [17]. Being under evaluation is not the same as being on the bulks list or approved for compounding. The accurate reading of mid-2026 is therefore narrow and real at once: a named substance, on the agenda, under evaluation, with no outcome assumed, stated, or dated [18].
## The Current FDA Fact, Stated Present-Tense
As of now, KPV — the C-terminal tripeptide (lysine-proline-valine) of alpha-MSH — is a research peptide and is not an FDA-approved drug for any indication [16][17]. There is no published human clinical trial of KPV, and no validated human dosing or safety data [13]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; substances not yet on that list are evaluated by FDA through a public nomination process informed by the Pharmacy Compounding Advisory Committee [17].
KPV is one of the bulk drug substances FDA has scheduled for PCAC evaluation [18]. That status is the whole of it: scheduled for evaluation. Being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding [17][18]. This page assigns KPV no numbered 503A category, because FDA's current, citable record for KPV is its place on the July 2026 evaluation agenda, not a category placement [18].
## How the 503A and 503B Framework Works
Under the Federal Food, Drug, and Cosmetic Act, two sections govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient [17]. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA registration and inspection [17].
The gating rule is about the ingredient. A compounder may use a bulk drug substance only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet on a list are evaluated through a public nomination process with PCAC input [17]. FDA's interim policy historically sorted nominated substances into numbered categories, and on January 7, 2025 FDA finalized a revised interim policy under which it no longer places newly nominated substances into those numbered categories [17][19]. Separately, FDA approval of a finished drug (a New Drug Application or Biologics License Application) is a different question from whether a bulk substance may be used in compounding — and KPV holds neither status [16][17].
## What This Means for Compounded Access
How does legally compounded peptide access work in general? A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [17]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [17].
Telehealth, where used, is simply the front-end channel for that prescriber-evaluation step; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate clinical relationship and a valid prescription [17]. The decisive caveat sits at the ingredient: a compounded preparation may lawfully be made only when its active ingredient is eligible under the 503A/503B framework, and a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [17]. For KPV, the operative fact today is simply that it is a research peptide under FDA evaluation, not yet on the bulks list [17][18].
This page names no specific pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain a substance outside the lawful framework. It is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply anything.
## Is KPV Legal?
KPV is a research peptide and is not an FDA-approved drug for any indication [16][17]. It is individually named on the published agenda of the July 23-24, 2026 PCAC meeting as a substance being considered for inclusion on the 503A bulks list — a scheduled discussion under evaluation, not a listing decision and not a change in current status [18]. Legality depends on jurisdiction and use-context; this page describes the U.S. compounding-regulatory landscape, not a blanket legal verdict, and is not legal advice.
## Can You Get KPV From a Compounding Pharmacy?
KPV is currently a research peptide under FDA evaluation and is not on the 503A bulks list, so it does not meet the bulk-substance eligibility tests (USP/NF monograph, component of an approved drug, or listing) for routine 503A compounding [17][18]. A licensed prescriber's evaluation alone does not make an ineligible ingredient eligible [17]. KPV is, however, scheduled for PCAC discussion in July 2026 as a candidate for the bulks list — an evaluation, not a decision [18].
## What Is the FDA 503A Status of KPV?
KPV is not an FDA-approved drug, and its current, FDA-citable status is that it is scheduled for evaluation: KPV (free base and acetate) is on the published agenda of the July 23-24, 2026 PCAC meeting as a substance being considered for inclusion on the 503A bulks list [16][18]. That is a scheduled discussion, not a listing decision or a reclassification, and being under evaluation is not the same as being on the bulks list or eligible for routine 503A compounding [17][18]. This site assigns KPV no numbered 503A category.
---
A friendly reading shelf of the KPV peptide literature — the in-vitro and mouse findings on this alpha-MSH tripeptide laid out gently, the absent human trials left honestly blank, and its FDA-evaluation standing noted before anything else; nothing here is a clinic, a prescription, or for sale.